首頁 > 市場調查報告書 > 製藥

開發平台分析

市場調查報告書

商品編碼

1789394

GLP-1 類似物市場：依藥物類型、品牌、用途、給藥途徑、類型、性別、年齡層、分銷管道及地區

Glucagon Like Peptide 1 Analogs Market, By Drug Type,, By Brand,, By Application,, By Route of Administration,, By Type,, By Gender,, By Age Group,, By Distribution Channel,, By Geography

出版日期: 2025年07月08日 | 出版商:

Coherent Market Insights | 英文 165 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

GLP-1 類似物市場規模預計在 2025 年達到 535 億美元，預計到 2032 年將達到 1,044.4 億美元，2025 年至 2032 年的複合年成長率為 10.1%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	535億美元
效能數據	2020-2024	預測期	2025-2032
預測期：2025-2032年複合年成長率：	10.10%	2032年預測	1044.4億美元

GLP-1類似物市場是糖尿病治療領域的一個革命性領域，它從根本上改變了第二型糖尿病和肥胖症管理的治療模式。 GLP-1類似物是天然存在的腸促胰島素激素GLP-1的合成版本，GLP-1透過刺激胰島素分泌、抑制升糖素分泌和減緩排放，在維持血糖穩態方面發揮關鍵作用。這些創新療法因其雙重作用機制：血糖控制和顯著減重，已成為治療的基石。

市場提供各種劑型，包括每日一次、每週一次和長效劑型，以滿足不同的患者偏好和治療通訊協定。主要企業正在大力投資研發，以透過先進的給藥系統來提高療效、減少副作用和改善患者依從性。全球糖尿病盛行率的上升以及人們對肥胖相關併發症認知的不斷提高，使GLP-1類似物成為醫療保健提供者的首選治療方案。這個細分市場持續經歷強勁成長，這得益於不斷擴大的臨床應用，包括降低心血管風險和潛在的神經保護作用，使其成為現代製藥業中最具活力和發展最快的領域之一。

市場動態

GLP-1類似物市場受到多個強勁促進因素的支撐，這些因素支撐著其強勁的成長軌跡。首先是全球第2型糖尿病和肥胖症的盛行率不斷上升，目前全球超過5.37億成年人受其影響，對有效的治療性介入的需求空前高漲。 GLP-1類似物卓越的療效，顯著降低糖化血紅蛋白（HbA1c）水平並顯著減輕體重，使其成為優於傳統糖尿病藥物的治療選擇。此外，越來越多的臨床證據支持其心血管保護作用以及在非酒精性脂肪肝病（NAFLD）中的潛在應用，拓寬了治療領域並推動了市場應用。包括緩釋性和創新注射裝置在內的藥物傳遞系統技術進步，正在提高患者的便利性和依從性，進一步刺激市場成長。然而，市場也面臨著許多限制因素，例如與傳統糖尿病藥物相比，GLP-1類似物價格高昂，這造成了藥物的可及性障礙，尤其是在價格敏感型市場，並且在某些地區保險覆蓋範圍有限。

噁心、嘔吐和腹瀉等消化器官系統道副作用會影響患者的依從性和治療保留率，阻礙市場滲透。肽基生技藥品的生產複雜性帶來了供應鏈挑戰和成本影響。然而，新興經濟體中尚未開發的市場也蘊藏著巨大的商機，這些地區的糖尿病盛行率正在迅速上升，同時醫療基礎設施得到改善，保險覆蓋範圍不斷擴大。 GLP-1 類似物與其他糖尿病藥物聯合治療的潛力提供了有利可圖的開發機會。此外，正在進行的對阿茲海默症、帕金森氏症和其他代謝紊亂等新適應症的研究可以將 GLP-1 類似物定位為糖尿病管理之外的多功能治療平台，從而顯著擴展潛在市場。

本次調查的主要特點

本報告對全球 GLP-1 類似物市場進行了詳細分析，並以 2024 年為基準年，展示了預測期（2025-2032 年）的市場規模和年複合成長率（CAGR%）。
它還強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
它根據公司亮點、產品系列、關鍵亮點、業績和策略等參數，概述了全球 GLP-1 類似物市場的主要企業。
本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、規模擴大、市場擴張和行銷策略做出明智的決策。
本研究報告針對該產業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 53.50 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	10.10%	2032 Value Projection:	USD 104.44 Bn

The glucagon like peptide 1 analogs market represents a revolutionary segment within the diabetes therapeutics landscape, fundamentally transforming treatment paradigms for Type 2 diabetes mellitus and obesity management. GLP-1 analogs are synthetic versions of the naturally occurring incretin hormone GLP-1, which plays a crucial role in glucose homeostasis by stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying. These innovative therapeutic agents have emerged as cornerstone treatments due to their dual mechanism of action, offering both glycemic control and significant weight reduction benefits.

The market encompasses various formulations including once-daily, once-weekly, and emerging longer-acting preparations, catering to diverse patient preferences and treatment protocols. Leading pharmaceutical companies have invested heavily in research and development to enhance drug efficacy, reduce side effects, and improve patient compliance through advanced delivery systems. The growing prevalence of diabetes worldwide, coupled with increasing awareness of obesity-related comorbidities, has positioned GLP-1 analogs as preferred therapeutic options among healthcare providers. This market segment continues to witness robust growth driven by expanding clinical applications, including cardiovascular risk reduction and potential neuroprotective effects, making it one of the most dynamic and rapidly evolving sectors in modern pharmaceutical industry.

Market Dynamics

The glucagon like peptide 1 analogs market is propelled by several compelling drivers that underscore its robust growth trajectory. The primary driver is the escalating global prevalence of Type 2 diabetes and obesity, with over 537 million adults currently living with diabetes worldwide, creating an unprecedented demand for effective therapeutic interventions. The superior efficacy profile of GLP-1 analogs, demonstrating significant HbA1c reduction alongside substantial weight loss benefits, positions these agents as preferred treatment options over traditional diabetes medications. Additionally, expanding clinical evidence supporting cardiovascular protective effects and potential applications in non-alcoholic fatty liver disease (NAFLD) broadens the therapeutic scope, driving market adoption. Technological advancements in drug delivery systems, including extended-release formulations and innovative injection devices, enhance patient convenience and adherence, further stimulating market growth. However, the market faces notable restraints, primarily the high cost of GLP-1 analogs compared to conventional diabetes treatments, creating accessibility barriers particularly in price-sensitive markets and limiting insurance coverage in certain regions.

Gastrointestinal side effects, including nausea, vomiting, and diarrhea, can impact patient compliance and treatment continuation, potentially hindering market penetration. Manufacturing complexities associated with peptide-based biologics pose supply chain challenges and cost implications. Nevertheless, significant opportunities emerge from untapped markets in developing economies where diabetes prevalence is rapidly increasing, coupled with improving healthcare infrastructure and expanding insurance coverage. The potential for combination therapies integrating GLP-1 analogs with other diabetes medications presents lucrative development opportunities. Furthermore, ongoing research into novel indications including Alzheimer's disease, Parkinson's disease, and other metabolic disorders could substantially expand the addressable market, positioning GLP-1 analogs as versatile therapeutic platforms beyond diabetes management.

Key Features of the Study

This report provides an in-depth analysis of the global glucagon like peptide 1 analogs market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global glucagon like peptide 1 analogs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Novo Nordisk, Eli Lilly and Company, Sanofi, AstraZeneca, Boehringer Ingelheim, Merck & Co., Amgen, GlaxoSmithKline, Bristol-Myers Squibb, Takeda Pharmaceutical Company, Daiichi Sankyo, Pfizer, Teva Pharmaceutical Industries, Regeneron Pharmaceuticals, Intarcia Therapeutics, and Hngzhou Jiuyuan Gene Engineering Co Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global glucagon like peptide 1 analogs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.

Market Segmentation

Drug Type Insights (Revenue, USD Bn, 2020 - 2032)
- Semaglutide
- Liraglutide
- Exenatide
- Dulaglutide
- Tirzepatide
- Others
- Linagliptin
- Lixisenatide
Brand Insights (Revenue, USD Bn, 2020 - 2032)
- Saxenda
- Victoza
- Ozempic
- Wegovy
- Rybelsus
- Trulicity Pen
- Zepbound
- Mounjaro
- BYDUREON BCise
- Others
Application Insights (Revenue, USD Bn, 2020 - 2032)
- Type 2 Diabetes Mellitus
- Weight Management (Obesity/Overweight)
- Cardiovascular Risk Reduction
Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Parenteral
Type Insights (Revenue, USD Bn, 2020 - 2032)
- Brand
- Generic
Gender Insights (Revenue, USD Bn, 2020 - 2032)
- Male
- Female
Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Adult
- Pediatric/Children
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Novo Nordisk
- Eli Lilly and Company
- Sanofi
- AstraZeneca
- Boehringer Ingelheim
- Merck & Co.
- Amgen
- GlaxoSmithKline
- Bristol-Myers Squibb
- Takeda Pharmaceutical Company
- Daiichi Sankyo
- Pfizer
- Teva Pharmaceutical Industries
- Regeneron Pharmaceuticals
- Intarcia Therapeutics
- Hngzhou Jiuyuan Gene Engineering Co Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Glucagon Like Peptide 1 Analogs Market, By Drug Type
- Glucagon Like Peptide 1 Analogs Market, By Brand
- Glucagon Like Peptide 1 Analogs Market, By Application
- Glucagon Like Peptide 1 Analogs Market, By Route of Administration
- Glucagon Like Peptide 1 Analogs Market, By Type
- Glucagon Like Peptide 1 Analogs Market, By Gender
- Glucagon Like Peptide 1 Analogs Market, By Age Group
- Glucagon Like Peptide 1 Analogs Market, By Distribution Channel
- Glucagon Like Peptide 1 Analogs Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Glucagon Like Peptide 1 Analogs Market, By Drug Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Semaglutide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Liraglutide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Exenatide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Dulaglutide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Tirzepatide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Linagliptin
Lixisenatide

5. Glucagon Like Peptide 1 Analogs Market, By Brand, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Saxenda
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Victoza
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Ozempic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Wegovy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Rybelsus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Trulicity Pen
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Zepbound
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Mounjaro
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
BYDUREON BCise
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Glucagon Like Peptide 1 Analogs Market, By Application, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Type 2 Diabetes Mellitus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Weight Management (Obesity/Overweight)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Cardiovascular Risk Reduction
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Glucagon Like Peptide 1 Analogs Market, By Route of Administration, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Glucagon Like Peptide 1 Analogs Market, By Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Brand
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Glucagon Like Peptide 1 Analogs Market, By Gender, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Glucagon Like Peptide 1 Analogs Market, By Age Group, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Pediatric/Children
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

11. Glucagon Like Peptide 1 Analogs Market, By Distribution Channel, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

12. Global Glucagon Like Peptide 1 Analogs Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Brand, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

13. Competitive Landscape

Novo Nordisk
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Takeda Pharmaceutical Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Daiichi Sankyo
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Regeneron Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Intarcia Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Hngzhou Jiuyuan Gene Engineering Co Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies

14. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

15. References and Research Methodology

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/價格

FAQ

GLP-1 類似物市場：依藥物類型、品牌、用途、給藥途徑、類型、性別、年齡層、分銷管道及地區

Glucagon Like Peptide 1 Analogs Market, By Drug Type,, By Brand,, By Application,, By Route of Administration,, By Type,, By Gender,, By Age Group,, By Distribution Channel,, By Geography

市場動態

目錄

第1章：調查目標和先決條件

第2章市場展望

第3章：市場動態、法規與趨勢分析

4. 2020-2032 年全球 GLP-1 類似物市場（依藥物類型）

5. 2020 年至 2032 年全球 GLP-1 類似物市場（依品牌）

6.全球GLP-1 類似物市場（按應用），2020 年至 2032 年

7.全球GLP-1 類似物市場（依給藥途徑），2020 年至 2032 年

8. 2020 年至 2032 年全球 GLP-1 類似物市場類型

9. 2020-2032 年全球 GLP-1 類似物市場（依性別）

10. 2020-2032 年全球 GLP-1 類似物市場（依年齡層）

11.全球GLP-1 類似物市場（依通路），2020 年至 2032 年

12.全球GLP-1 類似物市場（按地區），2020 年至 2032 年

第13章競爭格局

第 14 章分析師建議

第15章參考文獻與調查方法

Market Dynamics

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Glucagon Like Peptide 1 Analogs Market, By Drug Type, 2020-2032, (USD Bn)

5. Glucagon Like Peptide 1 Analogs Market, By Brand, 2020-2032, (USD Bn)

6. Glucagon Like Peptide 1 Analogs Market, By Application, 2020-2032, (USD Bn)

7. Glucagon Like Peptide 1 Analogs Market, By Route of Administration, 2020-2032, (USD Bn)

8. Glucagon Like Peptide 1 Analogs Market, By Type, 2020-2032, (USD Bn)

9. Glucagon Like Peptide 1 Analogs Market, By Gender, 2020-2032, (USD Bn)

10. Glucagon Like Peptide 1 Analogs Market, By Age Group, 2020-2032, (USD Bn)

11. Glucagon Like Peptide 1 Analogs Market, By Distribution Channel, 2020-2032, (USD Bn)

12. Global Glucagon Like Peptide 1 Analogs Market, By Region, 2020 - 2032, Value (USD Bn)

13. Competitive Landscape

14. Analyst Recommendations

15. References and Research Methodology

GLP-1 類似物市場：依藥物類型、品牌、用途、給藥途徑、類型、性別、年齡層、分銷管道及地區

Glucagon Like Peptide 1 Analogs Market, By Drug Type,, By Brand,, By Application,, By Route of Administration,, By Type,, By Gender,, By Age Group,, By Distribution Channel,, By Geography

市場動態

目錄

第1章：調查目標和先決條件

第2章 市場展望

第3章：市場動態、法規與趨勢分析

4. 2020-2032 年全球 GLP-1 類似物市場（依藥物類型）

5. 2020 年至 2032 年全球 GLP-1 類似物市場（依品牌）

6.全球GLP-1 類似物市場（按應用），2020 年至 2032 年

7.全球GLP-1 類似物市場（依給藥途徑），2020 年至 2032 年

8. 2020 年至 2032 年全球 GLP-1 類似物市場類型

9. 2020-2032 年全球 GLP-1 類似物市場（依性別）

10. 2020-2032 年全球 GLP-1 類似物市場（依年齡層）

11.全球GLP-1 類似物市場（依通路），2020 年至 2032 年

12.全球GLP-1 類似物市場（按地區），2020 年至 2032 年

第13章競爭格局

第 14 章分析師建議

第15章參考文獻與調查方法

Market Dynamics

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Glucagon Like Peptide 1 Analogs Market, By Drug Type, 2020-2032, (USD Bn)

5. Glucagon Like Peptide 1 Analogs Market, By Brand, 2020-2032, (USD Bn)

6. Glucagon Like Peptide 1 Analogs Market, By Application, 2020-2032, (USD Bn)

7. Glucagon Like Peptide 1 Analogs Market, By Route of Administration, 2020-2032, (USD Bn)

8. Glucagon Like Peptide 1 Analogs Market, By Type, 2020-2032, (USD Bn)

9. Glucagon Like Peptide 1 Analogs Market, By Gender, 2020-2032, (USD Bn)

10. Glucagon Like Peptide 1 Analogs Market, By Age Group, 2020-2032, (USD Bn)

11. Glucagon Like Peptide 1 Analogs Market, By Distribution Channel, 2020-2032, (USD Bn)

12. Global Glucagon Like Peptide 1 Analogs Market, By Region, 2020 - 2032, Value (USD Bn)

13. Competitive Landscape

14. Analyst Recommendations

15. References and Research Methodology

第2章市場展望